| Autor: |
Yonker ME; Pediatric Headache Program, Division of Neurology, AI DuPont Hospital for Children, 1600 Rockland Road, PO Box 269, Wilmington, DE 19899, USA. myonker@nemours.org |
| Jazyk: |
angličtina |
| Zdroj: |
Current pain and headache reports [Curr Pain Headache Rep] 2006 Oct; Vol. 10 (5), pp. 377-81. |
| DOI: |
10.1007/s11916-006-0063-6 |
| Abstrakt: |
Nonsteroidal anti-inflammatory drugs are the mainstay of migraine treatment for children and adolescents by most primary care physicians. Not all patients respond to these readily available agents. Triptans have been studied in children and adolescents, and there is reasonable evidence to support the use of these agents in these populations. Other agents, such as combination preparations and ergot compounds, are also used in clinical practice, although there has been little scientific study. Prophylactic agents have been less well studied in those under 18 years of age. Agents such as antidepressants, anticonvulsants, and antihypertensives are commonly used in clinical practice. Safety issues are fairly well understood because of historical use and use for other conditions. Efficacy and optimal dosing have yet to be established for the treatment of migraine in children and adolescents in double-blind, randomized, placebo-controlled trials. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink